CME Information

Target Audience

This activity is intended for community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with hematologic and oncologic malignancies.

Learning Objectives

After participating in the activity, participants should be better able to:

  • Strive for, and support other women in leadership positions in oncology
  • Foster team-based collaboration among women hematologists/oncologists, nurses, and other healthcare professionals
  • Acquire insights that help further personal and professional growth
  • Evaluate evidence regarding the impact of gender imbalance on patient care

Continuing Education

In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Bio Ascend. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Nebraska Medical Center designates this live activity for a maximum of 3.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Agenda

Time Event
11:00 AM
Welcome Remarks and Conference Introduction
11:15 AM
Professional Vignettes and Panel Discussion
12:00 PM
Oral Abstract/Poster Presentation: Mind the Gap:
Women Across Academic Oncology in 2021
12:05 PM
Leadership Skills: How to Lead in a Man’s World
1:05 PM
Lunch Break
1:35 PM
The Male Perspective on Closing the Gender Gap in Oncology Leadership Roles
2:05 PM
Oral Abstract/Poster Presentation:
Impact of COVID-19 Pandemic on Well-being and Work-related Burnout Among
Healthcare Workers at an Academic Center
2:10 PM
Moving Forward: Resiliency and Overcoming Challenges
2:55 PM
Wealth Wisdom: Seven Steps to Take Control of Your Financial Health
3:40 PM
Award Presentations: Woman Oncologist of the Year and Rising Star
3:55 PM
Closing Remarks and Adjourn
4:00 PM
Optional Networking Groups

Co-Chairs

Julie Brahmer, MD, MSc

Co-Director, Upper Aerodigestive Department
Professor of Oncology
Johns Hopkins Medicine
Baltimore, Maryland

Nina Shah, MD

Associate Professor
University of California San Francisco
San Francisco, California

Julie Vose, MD, MBA

Chief, Hematology/Oncology
Professor
University of Nebraska Medical Center
Omaha, Nebraska

Disclosure Information

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. Faculty (authors, presenters, speakers) are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or other options available when utilizing trade names to ensure impartiality.

All faculty, planners, and others in a position to control continuing education content participating in a UNMC accredited activity are required to disclose all financial relationships with ineligible companies. As defined by the Standards for Integrity and Independence in Accredited Continuing Education, ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC or Bio Ascend.

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles:  

Faculty

Monica Bertagnolli, MD, FACS, FASCO

Board of Directors:
American Cancer Society, Prevent Cancer Foundation, Leap Therapeutics, Natera, Inc., Oncoclinicas do Brasil Servicos Medicos

Research Funding to Alliance for Clinical Trials in Oncology Foundation:
AbbVie, Agenus, Astellas, AstraZeneca, Baxalta, Bayer HealthCare, Breast Cancer Research Foundation, Bristol-Myers Squibb, Celgene, Complion, Czarnowski, Derse, Inc., Eisai, Exelixis, Flame Biosciences, Genentech, GHI, Gilead Sciences, GSK Total, Incyte Corporation, Janssen, Jazz Pharma, Leap Therapeutics, Leidos, Lexicon Pharma, Lilly, Maltrex, Merck, Millennium, MITRE Corporation, Novartis, Pfizer, Pharmacyclics, Robert Wood Johnson FDN, Roche/Genentech, Sagerock Advisors, Sanofi, STO, Taiho Oncology, Takeda, Tesaro, Teva

Julie Brahmer, MD, MSc

Advisory Board:
Amgen, AstraZeneca, Bristol-Myers Squibb, Eisai, Eli Lilly, Genentech/Roche, Merck, Regeneron, Turning Point

Advisory Board/DSMB:
GlaxoSmithKline, Sanofi

Grant Funding to Institution: 
AstraZeneca, Bristol-Myers Squibb, Genentech

 

Michael Caligiuri, MD

Co-founder: 
CytoImmune Therapeutics, Precision Technologies

Consultant:
CBMG

Scientific Advisory Board:
Cytovia, Imugene, OncoC4

Narjust Duma, MD

Advisory Board: 
AstraZeneca, BI, BMS, Janssen, Pfizer

Elizabeth Jaffee, MD, FAACR, FACP

Consultant:
Achilles, Adaptive Biotech, Break Through Cancer Foundation, Candel, CSTONE, DragonFly, Genocea, NextCure, Parker Institute, Stimit

Grants:
AstraZeneca, Bristol-Myers Squibb, Genentech

Founder:
Abmeta

Bridget Keenan, MD, PhD

Research Funding:
Partner Therapeutics

Thomas Lynch, MD

Consultant and Stock Holder: 
Bristol-Myers Squibb

Board Member:
Hummingbird Bioscience, Kleo Pharmaceuticals

Elizabeth Plimack, MD, MS

Grants for Clinical Trial Conduct:
Astellas, Bristol-Myers Squibb, Genentech, Merck

Scientific Advisory:
AstraZeneca, Aveo, Bristol-Myers Squibb, Calithera, Genentech, Infinity Pharma, Janssen, MEI, Merck, Pfizer, Seattle Genetics

Nina Shah, MD

Consulting Fees:
Amgen, CareDx, GlaxoSmithKline, Indapta Therapeutics, Karyopharm, Kite, Oncopeptides, Sanofi

Research Funding:
Bluebird Bio, Celgene/BMS, Janssen, Nektar, Poseida, Sutro Biopharma, Teneobio

Rachna Shroff, MD, MS

Advisory Board Member:
AstraZeneca, BI, Clovis, Genentech, Incyte Corporation, Merck, QED Therapeutics, Servier, Taiho Oncology, Zymeworks

Julie Vose, MD, MBA

Consultant: 
MorphoSys

Advisory Board: 
AbbVie, AstraZeneca, Pharmacyclics

Karen Winkfield, MD, PhD

Consultant:
Bristol-Myers Squibb, Merck, Pfizer

The following faculty members have nothing to disclose:

Clifford Hudis, MD, FACP, FASCO
Jarushka Naidoo, MBBCH, MD
Julie Silver, MD
Carrie Thompson, MD, MS

Planning Committee

The following planning committee members have nothing to disclose:​
UNMC: Brenda Ram, CMP, CHCP​
Bio Ascend: Patti Bunyasaranand, MS; Lucja Grajkowska, PhD; Aimee Harwood

Support
This activity is supported by an independent educational grant from Pfizer, Inc.